← Back to Home

Testing Drugs in Brain Organoids First: Rare Epilepsy Study Finds a Treatment Lead for One Patient

Researchers grew brain organoids from patients’ cells to screen existing drugs. One patient experienced a reduced seizure burden after receiving a drug guided by the model. However, this two-patient study still has a substantial path of validation ahead before the approach can become a reliable clinical tool for selecting drugs.

By SURL BioNews

For patients with rare genetic epilepsy, finding an effective drug often means round after round of trial and error. Researchers are now exploring whether part of that process can be moved into a culture dish: first observing how brain organoids formed from patients’ cells respond to drugs, then using those responses to identify potential treatments. In a preliminary study, one patient experienced a reduced seizure burden after receiving a drug selected through this approach.

The American Society of Human Genetics (ASHG) announced this conference research on October 23, presented by Scott Younger of Children’s Mercy. Brain organoids are three-dimensional cellular models that can reproduce some biological features of a disease. The team had previously observed that organoids derived from patients with epilepsy showed excessive neuronal activity and that their responses to antiseizure medications aligned with the patients’ medical histories, prompting further testing of whether they could provide clues for personalized drug selection.

The first patient had severe epileptic encephalopathy caused by a gain-of-function variant in the CACNA1C gene. Within eight weeks, the team generated and completed the characterization of patient-derived brain organoids, then tested several calcium channel blockers approved by the U.S. Food and Drug Administration. One corrected the abnormal neural activity in the model. The patient subsequently received that drug and, according to the research team, experienced a marked reduction in seizure burden.

The second patient carried a truncating variant in the PPP3CA gene and had developmental and epileptic encephalopathy. This patient’s organoids also showed excessive neural activity and did not respond to an antiseizure medication that had been ineffective in the patient. The researchers also identified an FDA-approved calcineurin inhibitor that corrected the abnormalities in the model, but the press release did not report that this patient received the drug.

This study takes genetic diagnosis a step further: beyond identifying variants, it directly tests how patients’ cells respond to drugs. However, improvements in a culture dish still need to be validated individually against treatment effects in people. A drug’s approval also does not mean it is approved for these rare epilepsies or has been shown to be suitable for the patients concerned.

The evidence currently comes from only two patients, just one of whom received organoid-guided medication. The society’s press release did not provide drug names, the extent of seizure reduction, follow-up duration, or detailed safety data, so it is not yet possible to determine whether the improvement can be sustained or to establish causality. Larger studies are needed next to confirm whether this approach can consistently predict drug responses and actually improve patients’ treatment outcomes.

References

  1. American Society of Human Genetics